{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06118099",
            "orgStudyIdInfo": {
                "id": "ACT17967"
            },
            "secondaryIdInfos": [
                {
                    "id": "U1111-1290-9497",
                    "type": "REGISTRY",
                    "domain": "ICTRP"
                },
                {
                    "id": "2023-505803-22",
                    "type": "REGISTRY",
                    "domain": "CTIS"
                }
            ],
            "organization": {
                "fullName": "Sanofi",
                "class": "INDUSTRY"
            },
            "briefTitle": "Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",
            "officialTitle": "A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",
            "therapeuticArea": [
                "Other"
            ],
            "study": "proof-of-concept-study-evaluating-subcutaneous-amlitelimab-in-adult-participants-with-moderate-to-severe-hidradenitis-suppurativa"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-13",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01-14",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-31",
            "studyFirstSubmitQcDate": "2023-10-31",
            "studyFirstPostDateStruct": {
                "date": "2023-11-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sanofi",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS).\n\nThe purpose of this study is to measure standardized clinician reported and participant-reported outcomes (ClinRO and PRO), safety, and drug concentration. An optional long-term extension (LTE) period will assess chronic safety and efficacy over an additional 80 weeks of amlitelimab treatment.\n\nStudy details include:\n\n* The study duration will be up to 116 weeks, including a 4-week Screening period, a 16-week double-blind treatment period (DBT), an optional 80-week LTE period and a 16-week post-treatment follow-up period.\n* All participants who complete the 16-week DBT period will be offered entry into an optional LTE.\n* Participants who do not wish to enter the optional LTE period or who stop treatment prior to Week 16 (Visit 6) or stop investigational medicinal product (IMP) administration prior to completing the LTE period will proceed into the 16-week post-treatment follow-up period.\n* The number of planned in clinic visits will be up to six during the DBT period with an additional nine during the LTE period, plus one post-treatment follow-up end-of-study visit. Up to 11 optional in clinic visits are allowed for participants who do not wish to self-administer IMP between scheduled in clinic visits during the LTE period.",
            "detailedDescription": "The study duration per participant will be up to 116 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Hidradenitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 84,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Amlitelimab",
                    "type": "EXPERIMENTAL",
                    "description": "Subcutaneous injection (SC) as per protocol.",
                    "interventionNames": [
                        "Drug: Amlitelimab"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Subcutaneous injection as per protocol.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Amlitelimab",
                    "description": "Injection solution SC injection",
                    "armGroupLabels": [
                        "Amlitelimab"
                    ],
                    "otherNames": [
                        "SAR445229"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Injection solution SC injection",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The clinical response as measured by the percentage of participants achieving HiSCR50 at Week 16",
                    "description": "Hidradenitis suppurativa clinical response (HiSCR)50 is defined as \u226550% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.",
                    "timeFrame": "Week 16"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to onset of achieving HiSCR50",
                    "description": "HiSCR50 is defined as \u226550% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.",
                    "timeFrame": "From baseline to Week 16"
                },
                {
                    "measure": "Absolute change from baseline in AN count at Week 16",
                    "description": "AN count is the total abscess and inflammatory nodule count.",
                    "timeFrame": "Baseline to Week 16"
                },
                {
                    "measure": "Percentage change in AN count at Week 16",
                    "description": "AN count is the total abscess and inflammatory nodule count.",
                    "timeFrame": "Baseline to Week 16"
                },
                {
                    "measure": "Percentage of participants achieving HiSCR75 at Week 16",
                    "description": "HiSCR75 is defined as \u226575% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Percentage of participants achieving HiSCR90 at Week 16",
                    "description": "HiSCR90 is defined as \u226590% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count.",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Percentage of participants who experience improvement by at least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) stage at Week 16",
                    "description": "The IHS4 is a validated tool to assess HS severity. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Change in absolute score from Baseline in IHS4 at Week 16",
                    "description": "The IHS4 is a validated tool to assess HS severity. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.",
                    "timeFrame": "Baseline to Week 16"
                },
                {
                    "measure": "Percentage of participants who experience a flare at Week 16",
                    "description": "A flare is defined as at least a 25% increase in AN count (with a minimum increase of 2 AN) relative to baseline. AN count is the total abscess and inflammatory nodule count.",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Percentage of participants achieving IHS4-55 at Week 16",
                    "description": "IHS4-55 is defined as achievement of a 55% reduction in IHS4 score from baseline. A total score of 3 or less signifies mild, 4 to 10 signifies moderate, and 11 or higher signifies severe disease.",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Percentage of participants achieving at least 30% reduction and at least 1 unit reduction from Baseline in weekly average of daily HS-Skin Pain NRS at Week 16 among participants with baseline NRS \u22653",
                    "description": "Hidradenitis Suppurativa-Skin pain-numeric rating scale (HS-Skin pain NRS) is scored on a 0 to 10 scale with 0 indicating \"no skin pain\" and 10 indicating \"worst skin pain possible\".",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Percentage of participants with improvement (reduction) in Peak Pruritus Numerical Rating Scale (PP-NRS) \u22654 from Baseline at Week 16 among participants with baseline PP-NRS \u22654",
                    "description": "PP-NRS is a validated single item 0 (no itch) to10 (worst itch imaginable) numeric rating scale assessing peak pruritus (itch).",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Percentage of participants who experience 5-point reduction in DLQI at Week 16 among participants with baseline DLQI \u22654",
                    "description": "Dermatology life quality index (DLQI) is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL). Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.",
                    "timeFrame": "Week 16"
                },
                {
                    "measure": "Change from Baseline in the total Hidradenitis Suppurativa Quality of Life (HiSQOL) score at Week 16",
                    "description": "HiSQOL is an instrument designed to measure the HS-specific health-related QoL of adults with HS.",
                    "timeFrame": "Baseline to Week 16"
                },
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interest (AESIs), and serious adverse events (SAEs) including local injection site reactions in the Safety Population",
                    "timeFrame": "Baseline up to Week 116"
                },
                {
                    "measure": "Incidence of potentially clinically significant abnormalities in laboratory tests, vital signs, and electrocardiograms in the Safety Population",
                    "timeFrame": "Baseline up to Week 116"
                },
                {
                    "measure": "Serum amlitelimab concentrations measured at prespecified time points in the PK population",
                    "timeFrame": "Day 1 up to Week 116"
                },
                {
                    "measure": "Incidence of antidrug antibodies (ADA) of amlitelimab at prespecified timepoints in the ADA population",
                    "timeFrame": "Day 1 up to Week 116"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be 18 (or country's age of majority if \\>18) years to 70 years of age inclusive, at the time of signing the informed consent.\n* Participants with a history of signs and symptoms consistent with HS for at least 1 year prior to baseline.\n* Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), 1 of which must be Hurley Stage II or Hurley Stage III.\n* Participant must have had an inadequate response to at least a 12-week trial of an oral antibiotic for treatment of HS\n\nExclusion Criteria:\n\n* Participants with a diagnosis of inflammatory conditions other than HS (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, multiple sclerosis, Behcet's disease, sarcoidosis, etc)\n* Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trial Transparency email recommended (Toll free for US & Canada)",
                    "role": "CONTACT",
                    "phone": "800-633-1610",
                    "phoneExt": "option 6",
                    "email": "contact-us@sanofi.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Sciences & Operations",
                    "affiliation": "Sanofi",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Medical Dermatology Specialists Site Number : 8400002",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85006-2722",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "Center for Dermatology Clinical Research Site Number : 8400010",
                    "status": "RECRUITING",
                    "city": "Fremont",
                    "state": "California",
                    "zip": "94538-1601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.54827,
                        "lon": -121.98857
                    }
                },
                {
                    "facility": "Corazon USA, LLC (DBA Life Clinical Trials) Site Number : 8400011",
                    "status": "RECRUITING",
                    "city": "Margate",
                    "state": "Florida",
                    "zip": "33063",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.24453,
                        "lon": -80.20644
                    }
                },
                {
                    "facility": "Washington University School of Medicine Site Number : 8400007",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Centricity Research Site Number : 8400009",
                    "status": "RECRUITING",
                    "city": "Dublin",
                    "state": "Ohio",
                    "zip": "43016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.09923,
                        "lon": -83.11408
                    }
                },
                {
                    "facility": "Clinical Partners, LLC Site Number : 8400003",
                    "status": "RECRUITING",
                    "city": "Johnston",
                    "state": "Rhode Island",
                    "zip": "02919",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.82186,
                        "lon": -71.50675
                    }
                },
                {
                    "facility": "Center for Clinical Studies, LTD. LLP Site Number : 8400001",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77004",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Investigational Site Number : 0360003",
                    "status": "RECRUITING",
                    "city": "Phillip",
                    "state": "Australian Capital Territory",
                    "zip": "2606",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.13333,
                        "lon": 150.85
                    }
                },
                {
                    "facility": "Investigational Site Number : 0360001",
                    "status": "RECRUITING",
                    "city": "Darlinghurst",
                    "state": "New South Wales",
                    "zip": "2010",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.87939,
                        "lon": 151.21925
                    }
                },
                {
                    "facility": "Investigational Site Number : 0360002",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3004",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240007",
                    "status": "RECRUITING",
                    "city": "Barrie",
                    "state": "Ontario",
                    "zip": "L4M 7G1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 44.40011,
                        "lon": -79.66634
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240002",
                    "status": "RECRUITING",
                    "city": "Hamilton",
                    "state": "Ontario",
                    "zip": "L8L 3C3",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.25011,
                        "lon": -79.84963
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240001",
                    "status": "RECRUITING",
                    "city": "Quebec",
                    "zip": "G1W 4R4",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 46.81228,
                        "lon": -71.21454
                    }
                },
                {
                    "facility": "Investigational Site Number : 1520003",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Reg Metropolitana De Santiago",
                    "zip": "7580206",
                    "country": "Chile",
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Investigational Site Number : 1520001",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Reg Metropolitana De Santiago",
                    "zip": "7640881",
                    "country": "Chile",
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Investigational Site Number : 1520002",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Reg Metropolitana De Santiago",
                    "zip": "8380465",
                    "country": "Chile",
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500005",
                    "status": "RECRUITING",
                    "city": "La Rochelle",
                    "zip": "17019",
                    "country": "France",
                    "geoPoint": {
                        "lat": 46.16667,
                        "lon": -1.15
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500003",
                    "status": "RECRUITING",
                    "city": "Lyon",
                    "zip": "69003",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500001",
                    "status": "RECRUITING",
                    "city": "Reims",
                    "zip": "51100",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.25,
                        "lon": 4.03333
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500004",
                    "status": "RECRUITING",
                    "city": "Rouen",
                    "zip": "76031",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.44313,
                        "lon": 1.09932
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500002",
                    "status": "RECRUITING",
                    "city": "Saint Mande",
                    "zip": "94163",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.83864,
                        "lon": 2.41579
                    }
                },
                {
                    "facility": "Investigational Site Number : 2760002",
                    "status": "RECRUITING",
                    "city": "Bochum",
                    "zip": "44791",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.48165,
                        "lon": 7.21648
                    }
                },
                {
                    "facility": "Investigational Site Number : 2760001",
                    "status": "RECRUITING",
                    "city": "M\u00fcnster",
                    "zip": "48149",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.96236,
                        "lon": 7.62571
                    }
                },
                {
                    "facility": "Investigational Site Number : 3480004",
                    "status": "RECRUITING",
                    "city": "Budapest",
                    "zip": "1083",
                    "country": "Hungary",
                    "geoPoint": {
                        "lat": 47.49801,
                        "lon": 19.03991
                    }
                },
                {
                    "facility": "Investigational Site Number : 3480001",
                    "status": "RECRUITING",
                    "city": "Debrecen",
                    "zip": "4032",
                    "country": "Hungary",
                    "geoPoint": {
                        "lat": 47.53333,
                        "lon": 21.63333
                    }
                },
                {
                    "facility": "Investigational Site Number : 3480002",
                    "status": "RECRUITING",
                    "city": "Szeged",
                    "zip": "6720",
                    "country": "Hungary",
                    "geoPoint": {
                        "lat": 46.253,
                        "lon": 20.14824
                    }
                },
                {
                    "facility": "Investigational Site Number : 3800001",
                    "status": "RECRUITING",
                    "city": "Catania",
                    "zip": "95123",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 37.49223,
                        "lon": 15.07041
                    }
                },
                {
                    "facility": "Investigational Site Number : 3800002",
                    "status": "RECRUITING",
                    "city": "Cona (Ferrara)",
                    "zip": "44124",
                    "country": "Italy"
                },
                {
                    "facility": "Investigational Site Number : 6160001",
                    "status": "RECRUITING",
                    "city": "Warszawa",
                    "state": "Mazowieckie",
                    "zip": "02-507",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "Investigational Site Number : 6160004",
                    "status": "RECRUITING",
                    "city": "Warszawa",
                    "zip": "02-962",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "Investigational Site Number : 6160003",
                    "status": "RECRUITING",
                    "city": "Wroclaw",
                    "zip": "50-566",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 51.1,
                        "lon": 17.03333
                    }
                },
                {
                    "facility": "Investigational Site Number : 6200002",
                    "status": "RECRUITING",
                    "city": "Lisboa",
                    "zip": "1649-035",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 38.71667,
                        "lon": -9.13333
                    }
                },
                {
                    "facility": "Investigational Site Number : 6200001",
                    "status": "RECRUITING",
                    "city": "Lisboa",
                    "zip": "1998-018",
                    "country": "Portugal",
                    "geoPoint": {
                        "lat": 38.71667,
                        "lon": -9.13333
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240001",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "state": "Barcelona [Barcelona]",
                    "zip": "08041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240003",
                    "status": "RECRUITING",
                    "city": "Badalona",
                    "state": "Catalunya [Catalu\u00f1a]",
                    "zip": "08916",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.45004,
                        "lon": 2.24741
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240006",
                    "status": "RECRUITING",
                    "city": "Las Palmas de Gran Canaria",
                    "state": "Las Palmas",
                    "zip": "35010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 28.09973,
                        "lon": -15.41343
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240002",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "state": "Madrid, Comunidad De",
                    "zip": "28046",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017497",
                    "term": "Hidradenitis Suppurativa"
                },
                {
                    "id": "D000016575",
                    "term": "Hidradenitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000013543",
                    "term": "Sweat Gland Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000017192",
                    "term": "Skin Diseases, Bacterial"
                },
                {
                    "id": "D000001424",
                    "term": "Bacterial Infections"
                },
                {
                    "id": "D000001423",
                    "term": "Bacterial Infections and Mycoses"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000012874",
                    "term": "Skin Diseases, Infectious"
                },
                {
                    "id": "D000013492",
                    "term": "Suppuration"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19762",
                    "name": "Hidradenitis Suppurativa",
                    "asFound": "Hidradenitis Suppurativa",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18964",
                    "name": "Hidradenitis",
                    "asFound": "Hidradenitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16323",
                    "name": "Sweat Gland Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19500",
                    "name": "Skin Diseases, Bacterial",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4722",
                    "name": "Bacterial Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M12136",
                    "name": "Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M4721",
                    "name": "Bacterial Infections and Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M15677",
                    "name": "Skin Diseases, Infectious",
                    "relevance": "LOW"
                },
                {
                    "id": "M16273",
                    "name": "Suppuration",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}